drugset
drugset / Trial / NCT07044050

A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT07044050 ↗

Phase 1 Recruiting 10 enrolled Emercell SAS
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn the safety of OT-C001 and decide a good dose in treating relapsed or refractory diffuse large B-cell lymphoma patients. It will also learn about the preliminary activity of OT-C001. Participants will: Receive a short course of chemotherapy before OT-C001 treatment. During the study treatment, participants will recieve weekly dose of OT-C001 for 3 or 6 weeks. During the study period, participants will also receive another two drugs, rituximab and IL-2, to support OT-C001 treatment. Participants need to visit the clinic or may be hospitalized according to the study plan.

Timeline

Start
2025-06-10
Primary completion
2026-09-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject OT-C001 Cell therapy 1 unknown Intravenous
Subject OT-C001 Cell therapy 3 unknown Intravenous
Subject OT-C001 Cell therapy 1e+08 cells Intravenous

Indications

diffuse large B-cell lymphoma